Lexicon Pharmaceuticals, Inc. — FY 2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013. This is an annual filing, not a standalone fourth-quarter report; unaudited Q4 figures are noted below. Lexicon is a clinical-stage biopharmaceutical company with no commercial product sales, focusing resources mainly on LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome.
Financial results and liquidity
| Metric | FY 2013 | FY 2012 | Change / context |
|---|---|---|---|
| Revenue | $2.2 million | $1.1 million | Up 104%; principally collaborative research revenue |
| Research and development expense | $89.7 million | $82.6 million | Up 9%; higher external clinical development costs |
| General and administrative expense | $17.1 million | $17.0 million | Approximately flat |
| Operating loss | $102.4 million | $108.4 million | Narrowed |
| Net loss | $104.1 million | $110.2 million | Narrowed; loss per share was $0.20 versus $0.23 |
| Cash used in operating activities | $91.1 million | $94.5 million | Operating cash outflow |
| Cash, cash equivalents and short-term investments | $129.1 million | $223.2 million | Down $94.1 million |
| Working capital | $115.3 million | $212.7 million | Down $97.4 million |
| Long-term debt, net of current portion | $20.2 million | $21.9 million | Mortgage maturity extended to April 2017; fixed rate 8.23% |
Net cash from investing activities was $99.5 million, largely reflecting net investment maturities; financing activities used $1.4 million. The company reported no product revenue, so product margins are not applicable. Revenue was highly concentrated: McNair Medical Institute represented 57% and Taconic Farms 33% of 2013 revenue.
Q4 2013: Revenue was $1.410 million and net loss was $17.414 million, compared with revenue of $218,000 and net loss of $24.873 million in Q4 2012.
Material developments and pipeline
- LX4211: Preparing to begin pivotal Phase 3 trials in type 2 diabetes and seeking a development partner. The company reported favorable Phase 2b results in type 2 diabetes and statistically significant post-meal glucose reductions in a small renal-impairment trial. Enrollment in a 36-patient Phase 2 type 1 diabetes trial was completed in December 2013; results were not included.
- Telotristat etiprate (LX1032): A pivotal Phase 3 trial for carcinoid syndrome was ongoing. Prior Phase 2 results showed reductions in bowel movements and serotonin biomarker levels. The FDA had indicated that the single Phase 3 trial would need to provide compelling evidence of clinically meaningful benefit; additional pivotal testing could be required. The candidate had FDA Fast Track and Orphan Drug designations.
- Other programs: Phase 2 telotristat results in ulcerative colitis did not show statistically significant efficacy versus placebo. LX1033’s Phase 2 irritable bowel syndrome study also failed to show significant improvement in its primary endpoint versus placebo; further analyses were underway. LX2931’s earlier rheumatoid arthritis primary-endpoint improvement was not statistically significant.
- January 2014 subsequent event: The board decided to narrow research initiatives and prioritize late-stage programs. Lexicon planned to reduce its workforce by approximately 125, or about 50%, with most reductions in Q1 2014. Estimated costs were $6–$7 million, mostly cash expenditures.
Outlook, risks and unusual items
Management said existing resources and expected collaboration-related cash and revenue were expected to fund planned operations for at least 12 months from the filing. It also warned that later funding needs would be substantial, especially as programs advance, and that additional financing may not be available on acceptable terms. Lexicon planned to seek a partner for LX4211 Phase 3 development. No specific revenue, earnings or cash-flow guidance was provided.
- The company has a history of losses: accumulated deficit was $1.0 billion at year-end, and management expected continued losses. It depended on collaborations, licenses and milestone or royalty receipts and had no product sales.
- Clinical and regulatory outcomes are uncertain; early-stage results may not predict pivotal-trial success. For telotristat, an inadequate clinical benefit finding or a request for further Phase 3 trials could delay or prevent approval and add costs.
- Competition, third-party manufacturing dependence, intellectual-property challenges, reimbursement and commercialization requirements, and collaborator performance could materially affect prospects.
- Invus and affiliates held approximately 55.1% of outstanding common stock, with related board designation, preemptive and consent rights.
- The Symphony Icon purchase liability’s fair value decreased $2.2 million in 2013, versus increases of $9.9 million in 2012 and $6.8 million in 2011. These non-cash valuation changes affected reported operating expenses and year-to-year comparisons.
- A Texas Enterprise Fund award carries potential repayment exposure for job-creation shortfalls, up to approximately $14.2 million before credits. The filing described ordinary-course legal proceedings as not expected to have a material adverse effect.
Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. Management also concluded disclosure controls were effective.
Key facts for investors to verify
- Enrollment, timing and results of the LX4211 and telotristat pivotal or late-stage trials, and whether Lexicon secures a development partner.
- Actual cash burn and runway following the workforce reduction, including restructuring costs and any financing or collaboration proceeds.
- Whether revenue concentration changes and whether collaborations generate meaningful future milestones or royalties.
- Regulatory feedback on whether the telotristat Phase 3 evidence is sufficient and whether additional trials will be needed.
- Implementation and financial effects of the workforce reduction, and any eventual Texas job-award repayment obligation.